Same Data, Same Day, Different Decision: FDA, EMA On Roche's Protease Inhibitor Invirase
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA goes for a new warning and a MedGuide; EMA calls for a lower starting dose.
You may also be interested in...
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.
FDA, EMA Decisions On Avandia Reflect The Power Of REMS
Contrasting decisions by FDA and the European Medicines Agency on the fate of GlaxoSmithKline’s Avandia reflect not so much a divergence of scientific opinion between the two regulators, but rather differences in how they chose to manage the drug’s cardiovascular risks and the tools available for doing so.
AstraZeneca's Ticagrelor Gets Positive EU Recommendation, But FDA Could Catch Up Soon
Europe's CHMP recommends ticagrelor for patients with acute coronary syndromes, while FDA still grapples with lack of effect in North American patients.